Related Experiment Video
Updated: Jun 26, 2026

Three Different Protocols of Corneal Collagen Crosslinking in Keratoconus: Conventional, Accelerated and Iontophoresis
Published on: November 12, 2015
Corneal Cross-Linking for Pediatric Keratoconus
Bogumiła Wójcik-Niklewska1,2, Erita Filipek1,2, Paweł Janik3
1Department of Pediatric Ophthalmology, Faculty of Medical Sciences in Katowice, Medical University of Silesia, 40-055 Katowice, Poland.
Insights
Corneal cross-linking (CXL) effectively halts keratoconus progression in pediatric patients. Long-term ophthalmic monitoring is recommended for those under 18 post-procedure.
Area of Science:
- Ophthalmology
- Corneal Surgery
- Pediatric Eye Care
Background:
- Keratoconus is a progressive corneal ectasia affecting young individuals.
- Early intervention is crucial to prevent vision loss.
- Corneal cross-linking (CXL) is a standard treatment for keratoconus.
Purpose of the Study:
- To evaluate the efficacy of corneal cross-linking (CXL) in pediatric patients with keratoconus.
- To assess changes in visual acuity, intraocular pressure, keratometry, and pachymetry after CXL.
- To determine if CXL can halt or slow keratoconus progression in children.
Main Methods:
- 111 eyes of 74 pediatric patients (mean age 15 years) with keratoconus underwent CXL.
- The Amsler-Krumeich system was used for keratometric qualification.
- Corneal collagen cross-linking involved ultraviolet light and riboflavin drops.
- Parameters analyzed included visual acuity, intraocular pressure, keratometry, and pachymetry pre- and post-procedure.
Main Results:
- No statistically significant changes were observed in visual acuity, intraocular pressure, or astigmatism post-CXL.
- Mean keratometry showed a slight, non-significant decrease after CXL.
- A statistically significant reduction in mean corneal thickness (pachymetry) was noted post-CXL.
Conclusions:
- Corneal cross-linking (CXL) is an effective treatment for preventing keratoconus progression in pediatric patients.
- While CXL appears safe and effective, continued ophthalmic follow-up is essential for pediatric patients.
- Further detailed follow-up is highly advisable for individuals under 18 who have undergone CXL.
Aim:
The aim of this study was to evaluate corneal cross-linking (CXL) for keratoconus in pediatric patients.
Materials And Methods:
After keratometric qualification according to the Amsler-Krumeich system, corneal collagen cross-linking was performed using ultraviolet light and photosensitizing riboflavin drops in 111 eyes of 74 children with a mean age of 15 ± 1.67 years. None of the children studied wore contact lenses before the procedure. Visual acuity, intraocular pressure, keratometry, and pachymetry parameters were analyzed before and after corneal cross-linking.
Results:
Visual acuity was 0.64 ± 0.31 and 0.66 ± 0.29 before CXL and at the end of the follow-up, respectively; the difference was not statistically significant. The mean intraocular pressure before CXL was 14.48 ± 3.13 mmHg, while the mean value at the end of the follow-up was 14.23 ± 3.03 mmHg; no statistically significant difference was found. Pre- and post-CXL astigmatism was 3.98 ± 2.34 Dcyl and 3.63 ± 1.86 Dcyl, respectively; the difference was not statistically significant. The mean keratometry before CXL was 47.99 ± 3.96 D; the mean post-follow-up value was 47.74 ± 3.63 D. The mean corneal thickness (pachymetry) at the apex of the keratoconus-the thinnest zone of the cornea-before CXL was 492.16 ± 38.75 µm, while the mean value at the end of the follow-up was 479.99 ± 39.71 µm; the difference was statistically significant.
Conclusions:
Corneal cross-linking is an effective method for preventing keratoconus progression in children. However, further and detailed ophthalmic follow-up of patients who underwent CXL before the age of 18 is highly advisable.
More Related Videos
05:56Scleral Cross-linking Using Riboflavin and Ultraviolet-A Radiation for Prevention of Axial Myopia in a Rabbit Model
Published on: April 3, 2016
12:25Second Harmonic Generation Signals in Rabbit Sclera As a Tool for Evaluation of Therapeutic Tissue Cross-linking TXL for Myopia
Published on: January 6, 2018
Related Concept Videos
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment